PBYI Puma Biotechnology Inc

Price (delayed)

$5.27

Market cap

$214.91M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.89

Enterprise value

$237.5M

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights ...

Highlights
Puma Biotechnology's equity has surged by 79% QoQ and by 26% YoY
PBYI's EPS is down by 33% since the previous quarter but it is up by 16% year-on-year
The net income has contracted by 32% from the previous quarter but it has grown by 16% YoY
Puma Biotechnology's gross margin has decreased by 10% YoY and by 3.2% from the previous quarter
PBYI's gross profit is down by 9% QoQ and by 5% YoY

Key stats

What are the main financial stats of PBYI
Market
Shares outstanding
40.78M
Market cap
$214.91M
Enterprise value
$237.5M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.22
Price to sales (P/S)
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.93
Earnings
Revenue
$254.86M
EBIT
-$20.59M
EBITDA
-$8.82M
Free cash flow
$11.64M
Per share
EPS
-$0.89
Free cash flow per share
$0.29
Book value per share
$0.73
Revenue per share
$6.3
TBVPS
$4.69
Balance sheet
Total assets
$260M
Total liabilities
$230.53M
Debt
$121.29M
Equity
$29.47M
Working capital
$29.85M
Liquidity
Debt to equity
4.12
Current ratio
1.22
Quick ratio
1.08
Net debt/EBITDA
-2.56
Margins
EBITDA margin
-3.5%
Gross margin
75.5%
Net margin
-13.7%
Operating margin
-7.8%
Efficiency
Return on assets
-13.7%
Return on equity
-354.8%
Return on invested capital
-26.6%
Return on capital employed
-16.9%
Return on sales
-8.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PBYI stock price

How has the Puma Biotechnology stock price performed over time
Intraday
-7.38%
1 week
-10.98%
1 month
-22.73%
1 year
-44.53%
YTD
-48.64%
QTD
-24.82%

Financial performance

How have Puma Biotechnology's revenue and profit performed over time
Revenue
$254.86M
Gross profit
$192.46M
Operating income
-$19.77M
Net income
-$35.04M
Gross margin
75.5%
Net margin
-13.7%
Puma Biotechnology's net margin has decreased by 40% QoQ but it has increased by 21% YoY
The operating margin has grown by 38% YoY
The operating income has grown by 35% YoY
The net income has contracted by 32% from the previous quarter but it has grown by 16% YoY

Growth

What is Puma Biotechnology's growth rate over time

Valuation

What is Puma Biotechnology stock price valuation
P/E
N/A
P/B
7.22
P/S
0.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.93
PBYI's EPS is down by 33% since the previous quarter but it is up by 16% year-on-year
Puma Biotechnology's equity has surged by 79% QoQ and by 26% YoY
PBYI's P/B is 76% lower than its 5-year quarterly average of 30.6
PBYI's P/S is 99% below its 5-year quarterly average of 58.7 and 48% below its last 4 quarters average of 1.6
The revenue has contracted by 6% from the previous quarter but it has grown by 6% YoY

Efficiency

How efficient is Puma Biotechnology business performance
PBYI's ROIC has shrunk by 94% QoQ and by 26% YoY
PBYI's return on sales has dropped by 84% since the previous quarter but it is up by 32% year-on-year
Puma Biotechnology's ROE has decreased by 44% YoY and by 12% from the previous quarter
The ROA has decreased by 33% QoQ but it has increased by 21% YoY

Dividends

What is PBYI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PBYI.

Financial health

How did Puma Biotechnology financials performed over time
The total assets is 13% more than the total liabilities
The company's current ratio fell by 27% YoY but it rose by 4.3% QoQ
Puma Biotechnology's quick ratio has decreased by 27% YoY but it has increased by 4.9% from the previous quarter
Puma Biotechnology's equity has surged by 79% QoQ and by 26% YoY
Puma Biotechnology's debt to equity has decreased by 44% QoQ and by 20% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.